Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant encorafenib + binimetinib + cetuximab in BRAF V600E pMMR localized colorectal cancer
2020-005771-12Phase 2Terminated
- Sponsor
- AIO-Studien
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab, encorafenib and binimetinib in colorectal cancer (CRC), colon cancer and rectal cancer, sponsored by AIO-Studien. Primary endpoint: Tumor regression grade (TRG). Started Feb 2022; status: terminated.
02
Drugs
cetuximabencorafenibbinimetinib
03
Conditions
colorectal cancer (CRC)colon cancerrectal cancer
Beyond the preview
Go deeper on 2020-005771-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005771-12.